Takeda Vaccines, Inc.

The invention relates to a unit dose of a dengue vaccine composition and methods and uses for preventing dengue disease and methods for stimulating an immune response to all four dengue virus serotypes in a subject or subject population. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

The present invention relates to a method for determining the infectivity of a virus, in particular a flavivirus. Further, a method for determining the titer of a virus-specific antibody in a sample is provided. In addition, the use of the method in the quality control of vaccines and in the diagnosis of an infection are provided as well. The present invention also provides a method for determining the proportion of infectious virus particles in a sample comprising infectious and non-infectious virus particles. The present invention further relates to a maturation assay for determining the average maturation degree. The present invention also relates to novel anti-dengue virus serotype 2 (DENV2) and anti-dengue virus serotype 4 (DENV4) antibodies and antigen binding fragments thereof being useful in the method of the invention. Further, nucleic acids encoding them and host cells comprising them are provided. In addition, the use of the antibodies in the prevention or treatment of dengue disease is provided. Also, diagnostic methods using them and kits comprising them are provided.

The present invention relates to a dengue vaccine formulation comprising a tetravalent dengue virus composition comprising a live attenuated dengue virus serotype 1, a live attenuated dengue virus serotype 2, a live attenuated dengue virus serotype 3, and a live attenuated dengue virus serotype 4, at least one non-reducing disaccharide, at least one poloxamer, urea, at least one amino acid having a positively charged side chain at neutral pH, tromethamine, and human serum albumin.

A dengue vaccine for use in a method of protecting against dengue disease in a pregnant and/or breastfeeding human subject.

The present invention relates to anti-dengue virus serotype 3 (DENV3) antibodies and antigen binding fragments thereof. Further, nucleic acids encoding them and host cells comprising them are provided. In addition, the use of the antibodies in the prevention or treatment of dengue disease is provided. Also, diagnostic methods using them and kits comprising them are provided.

The present disclosure relates to vaccines and immunogenic compositions comprising an antigen from a Zika virus (e.g., wherein the antigen is an inactivated whole Zika virus), and their use in medical applications (such as methods of treatment).

The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.

A computer-implemented method of determining confluence of a cell culture is provided. The method comprises receiving (S 1 ), with a computing device ( 10 ), image data ( 200 ) indicative of an image ( 201 ) of at least a part of a container ( 50 ) comprising a cell culture ( 51 ), splitting (S 2 ) the image data ( 200 ) into a plurality of chunks ( 202 ), wherein each chunk is associated with an image portion ( 203 ) of the image ( 201 ), classifying (S 3 ) the plurality of chunks ( 202 ) into at least a first class ( 202 a ) and a second class of chunks ( 202 b ), the first class being representative of chunks ( 202 a ) associated with an image portion ( 203 ) including a cellular object and the second class being representative of chunks ( 202 b ) associated with an image portion ( 203 ) including cell-free area, and computing (S 4 ) a confluence value based on determining, for at least a subset of chunks ( 202 b ) classified into the second class, a number of chunks having at least one neighboring chunk ( 202 b ) classified into the second class.

A computer-implemented method of determining infectivity of a flavivirus-containing sample is described. The method includes receiving (S 1 ), with a computing device ( 10 ), image data indicative of an image of at least a part of a container ( 50, 50 a, 50 b ) comprising a composition containing host cells with one or more foci ( 51 ) generated by infecting the host cells with the flavivirus over an incubation period and optionally subsequent staining of the incubated host cells. The method further includes determining (S 2 ) a number of foci ( 51 ) in the at least part of the container ( 50, 50 a, 50 b ) based on processing the received image data with at least one trained deep learning algorithm of the computing device ( 10 ), wherein the number of foci ( 51 ) is indicative of the infectivity of the flavivirus in the sample.